9.15 - 16.30 EST | 6.15 - 13.30 PST
Day One
Wednesday May 5 2021
9:15 am Opening Remarks from Chairperson
9:30 am Keynote Presentation from Gilead Sciences: Preclinical Development of Toll-like Receptor Agonists for Chronic HBV Infection
Integrating New Learnings About Chronic HBV Infection & Lifecycle into the Next Generation of Therapeutics
10:00 am Understanding the immune response to HBV in chronically infected patients: Implication for immunotherapy design
Synopsis
- Immune responses to HBV in chronic infection are complex
- There is an emerging need to characterise these responses in detail using standardized methods
- This might have a big impact in the design of effective immunotherapy strategy
To read full session information – download the event guide here.
10:30 am Virtual Speed Networking Break
Synopsis
Grab a quick cup of tea or coffee from the comfort of your own home office and jump straight into your opportunity to connect with new contacts from active companies in the field and exchange digital business cards. Network and form lasting connections through this exclusive virtual speed networking!
To read full session information – download the event guide here.
11:00 am Curing Chronic HBV Infection Guided by HBV Infection Biology
Synopsis
- A different view of HBV cccDNA persistence through HBV infection biology
- A new HBV cure strategy devised by HBV infection biology
- A new HBV therapeutic that implements this new HBV cure strategy
To read full session information – download the event guide here.
11:30 am Towards a Curative Therapy for Hepatitis B and D Co-Infected Patients: A Pivotal Role for Entry Inhibition with Myrcludex B/ Bulevirtide Alone or in Combination with Peg-IFN-alpha
Synopsis
- Provide insights into the mechanisms of persistence of HBV and HDV episomes.
- Clarify the role of entry inhibition for curative therapeutic approaches.
- Sum up the clinical data on bulevirtide in mono- and pegIFN-combination therapy
To read full session information – download the event guide here.
12:00 pm Harnessing New Knowledge of HBV Replication Cycle for Antiviral Discovery
Synopsis
To read full session information – download the event guide here.
12:30 pm Virtual Networking Break
Preclinical Analysis of Novel Chronic Hep B Therapeutics
1:30 pm A Robust HBV Infected 3D Culture Model for Evaluate Efficacy Of Galnac-Oligos In Vitro
Synopsis
- Chronic HBV is characterized by immune tolerance, and functional cure can only be achieved by restoring T cell function
- Prior efforts in HBV immunotherapeutics have focused the surface antigen and full-length proteins or on nonspecific immune enhancement using TLR agonists or PD-1 inhibitors. Efficacy and safety of this approach will be enhanced by targeting highly conserved epitopes on core and polymerase proteins and assuring immune responses across the range of HBV genotypes.
- An immunotherapeutic agent will be effective at an HBsAg level at which immune tolerance is restored (below 100 IU/mL). Combination therapy with one of the new direct acting agents may achieve this starting point for treatment
To read full session information – download the event guide here.
Advancing Emerging Therapeutics for Chronic Hepatitis B Infection Through the Clinic
2:00 pm Managing Potential Drug-Induced Liver Injuries During Clinical Trials for Novel HBV Therapies
2:30 pm Development of a Therapeutic Vaccine for Hepatitis B
Synopsis
- Vaccine to achieve functional cure through induction of CD8+ T cells
- In Phase 1/2a
- Based on consensus genotype C
To read full session information – download the event guide here.
3:00 pm Virtual Speed Networking Break
3:30 pm Immtav® Molecules for The Treatment Of Hepatitis B
Synopsis
- First HLA-A2 clinical candidate, IMC-I109V, shows potency in vitro
- Development of the ImmTAX platform to target HLA-E, a nonpolymorphic allele
- In vitro potency data with HLA-E specific ImmTAVs
To read full session information – download the event guide here.
4:00 pm An RNAi for the Treatment Of Chronic Hepatitis B Infection: Clinical Update
Synopsis
- There is a huge unmet need for new chronic hepatitis B treatments
- siRNAs represent a promising new mechanism of action for the treatment of chronic hepatitis B
- AB-729 reduces HBsAg and other HBV biomarkers in different HBV patient populations
To read full session information – download the event guide here.